Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up Study on Resistance and Durability of Response to AbbVie Direct-Acting Antivirals
2015-000452-24Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glecaprevir in hepatitis C virus infection, sponsored by AbbVie Inc. Primary endpoints: Sustained virologic response durability and Persistence of resistance-associated amino acid variants. Started Dec 2016; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-000452-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000452-24.